TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06039215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilatory adjustments by nurses
Description: Respirator settings are adjusted by nurses according to a pre-established care protocol that complies with international recommendations. The nurse assesses the patient's respiratory status and readjusts the artificial respirator settings if necessary, at least twice a day.
Study: NCT05641012

Intervention type: OTHER
Intervention: data collection
Description: helioderma evaluation
Study: NCT06003218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-esketamine combination
Description: Dexmedetomidine-esketamine mixture will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone will be injected intravenously 10-15 min before puncture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone will be injected intravenously 10-15 min before puncture.
Study: NCT05706870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GN-037
Description: GN-037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol 17-propionate
Description: Clobetasol 17-propionate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06092255

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy for SVZ
Description: GBM patients who met the inclusion criteria received radiotherapy range and dose based on the EORTC outline principles. The ipsilateral and contralateral SVZ areas received 56Gy and 40Gy respectively, with a fractionated dose of 2Gy. Concurrent chemotherapy with temozolomide and six cycles of adjuvant temozolomide chemotherapy were performed at the same time as radiotherapy.
Study: NCT06013410

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: colonoscopy
Study: NCT05392335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial stretch
Description: Myofascial stretch will be applied at hip adductors, hamstrings and calf muscles for 10 -15 repetitions on each muscle. 2-3 sessions will be performed in a week for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial stretch
Description: Myofascial stretch will be applied at hip adductors, hamstrings and calf muscles for 10 -15 repetitions on each muscle. 2-3 sessions will be performed in a week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional massage along with myofacial stretch
Description: In this group during the first 20 minutes, ten minutes FM will be applied to each lower extremity of the subject. The muscle groups to which FM would be applied were hip adductors, hamstrings and calf muscles. During the remaining period traditional physiotherapy involving myofascial strecth will be given. 2-3 session will be performed in a week for 8 weeks.
Study: NCT05257395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287+ Letrozole/Anastrozole
Description: XZP-3287 360 mg orally after meals Twice daily of every 28-day cycle; Letrozole tablets 2.5mg orally once daily of every 28-day cycle or Anastrozole tablets 1mg orally once daily of every 28-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Letrozole/Anastrozole
Description: Placebo 360 mg orally after meals Twice daily of every 28-day cycle; Letrozole tablets 2.5mg orally once daily of every 28-day cycle or Anastrozole tablets 1mg orally once daily of every 28-day cycle
Study: NCT04929353

Intervention type: OTHER
Group type: OTHER
Intervention: Systematic symptom assessment
Description: * Systematic symptom assessment~* Conventional symptom assessment

Intervention type: OTHER
Group type: OTHER
Intervention: Systematic symptom assessment
Description: * Systematic symptom assessment~* Conventional symptom assessment
Study: NCT05000424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clary Sage Massage Oil
Description: This massage oil contains clary sage oil. Five drops will be used daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inert Massage Oil
Description: This massage oil consists entirely of plant based oils. Five drops will be used daily.
Study: NCT04999917

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: high-resolution PET-CT specimen imaging.
Description: A single intravenous injection of 18F-FDG (0.80 MBq/kg) is given between 30 minutes and 3 hours before tumor resection.~Surgical resection of the breast tumor (= main specimen) under general anesthesia.~The main specimen is imaged using the Aura 10 PET-CT Specimen Imager (XEOS Medical, Ghent, Belgium). In case of positive margins, the surgeon will perform oriented cavity shaving. The cavity shaves and lymph nodes (if any) are also imaged using the Aura 10 PET-CT Specimen Imager (for scientific purposes only).~The main specimen and if applicable the cavity shaves and lymph node(s) are processed following standard-of-care routine: from tissue samples to HE-stained and IHC-stained sections. The histopathological margin status shall be reported according to the ASCO-CAP guidelines, and shall be compared to the PET-CT images of the resected specimens.
Study: NCT06180889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 40 mg enoxaparin administered as subcutaneous injection once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN060 Low
Description: Single dose of KN060 administered as intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN060 Middle
Description: Single dose of KN060 administered as intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN060 Hight
Description: Single dose of KN060 administered as intravenous infusion
Study: NCT06383689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seizure placebo pill
Description: patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible acceleration of seizure occurrence during presurgical video-EEG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Well-being placebo pill
Description: patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible improvement of emotional well-being during video-EEG
Study: NCT05098418

Intervention type: DRUG
Intervention: Poison
Description: standard of care and propre antidotes will be provided for each poisoned patients in addition to gastric lavage and activated charcoal administration when it is applicable

Intervention type: DRUG
Intervention: Poison
Description: standard of care and propre antidotes will be provided for each poisoned patients in addition to gastric lavage and activated charcoal administration when it is applicable

Intervention type: DRUG
Intervention: Poison
Description: standard of care and propre antidotes will be provided for each poisoned patients in addition to gastric lavage and activated charcoal administration when it is applicable

Intervention type: DRUG
Intervention: Poison
Description: standard of care and propre antidotes will be provided for each poisoned patients in addition to gastric lavage and activated charcoal administration when it is applicable

Intervention type: DRUG
Intervention: Poison
Description: standard of care and propre antidotes will be provided for each poisoned patients in addition to gastric lavage and activated charcoal administration when it is applicable
Study: NCT05071443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Description: The therapeutic intervention being tested is the use of a negative pressure wound therapy (NPWT) device. Several medical devices are currently being used and are based on the same principle. They involve applying negative pressure, generally between -100 and -150 mmHg, to a wound using a dressing (mostly a polyurethane foam dressing with hydrophobic pores), which hermetically covers the wound's surface and is connected to a container for collecting the fluids drained off. These devices are widely available and used to treat post-operative wounds.~Duration of treatment: the use of NPWT will be maintained until the recovery of the skin has been achieved by the skin graft. An average duration of 3 weeks' treatment is expected in the intervention group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dressing
Description: Conventional dressings will be performed from randomization to skin grafting and applied every day based on the methods normally used in the participating centres, and also until the recovery of the skin has been achieved by the skin graft.~This generally involves local care provided on a daily basis, ensuring gentle mechanical and chemical debridement by covering the wound with alginate type or other dressings, according to the condition of the wound. The methods used to apply these conventional dressings will be recorded.
Study: NCT05200728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM1910-09
Description: Part A-single ascending doses， SIM1910-09 will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, SIM1910-09 will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion，which will be tested sequentially from low dose to high dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A-single ascending doses， placebo will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, placebo will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion，which will be tested sequentially from low dose to high dose.
Study: NCT06219915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa 25 mg
Description: Participants will take one 25mg Carbidopa tablet 3 times a day for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa-Levodopa 25/100 mg
Description: Participants will take one 25/100mg carbidopa-levodopa tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Participants will take one 25mg placebo tablet 3 times a day for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: Participants will take one 100mg placebo tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
Study: NCT05227495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR cognitive training
Description: All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~They will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional cognitive training
Description: All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program.
Study: NCT06184230

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis A Vaccine
Description: Hepatitis A Vaccine
Study: NCT06300567

Intervention type: OTHER
Intervention: data collection
Description: collection of data of generated by real world follow up
Study: NCT05651841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab is supplied as a sterile, single-use, preservation-free, clear, colourless to slightly yellow liquid for subcutaneous administration in accessorized pre-filled syringes (APFS).~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram.
Study: NCT06354010

Intervention type: GENETIC
Intervention: Genotyping
Description: Genotyping to determine if patients present mutations to the gene GJB2.

Intervention type: OTHER
Intervention: Audiological assessments
Description: Audiological assessments
Study: NCT05651841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab is supplied as a sterile, single-use, preservation-free, clear, colourless to slightly yellow liquid for subcutaneous administration in accessorized pre-filled syringes (APFS).~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab is supplied as a sterile, single-use, preservation-free, clear, colourless to slightly yellow liquid for subcutaneous administration in accessorized pre-filled syringes (APFS).~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: APFS containing analogous placebo identical in appearance:~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: APFS containing analogous placebo identical in appearance:~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram.
Study: NCT06030973

Intervention type: BEHAVIORAL
Intervention: Filling in an online survey
Description: Professionals are asked to complete questions regarding 1) the degree of current participation in a registry, 2) the need for a European registry, 3) the items that should be collected and 4) access to the European registry.
Study: NCT05799703

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrical stimulation device
Description: the device has 2 channels ,4 electrodes with multiple ems programs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesio taping
Description: kinesio tape a therapeutic tape that's applied strategically to the body to provide support, lessen pain, reduce swelling, and improve performance
Study: NCT05519111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol, an FDA approval oral agent containing synthetic tetrahydrocannabinol (THC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo equivalent
Study: NCT04635826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall 10Mg Tablet
Description: Participants will be administered Adderall

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall 10Mg Tablet
Description: Participants will be administered Adderall

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be administered placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered placebo
Study: NCT05679583

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative Stereotactic body radiation therapy (SBRT), Pancreatic resection, Adjuvant Chemotherapy
Description: 1. Preoperative Stereotactic body radiation therapy (SBRT) For the gross pancreatic cancer lesion, 30 Gy/5 fx will be prescribed considering respiratory movement. And 20 Gy/5 fx will be prescribed to the triangle operation area including the common hepatic artery, celiac artery, and portal vein.~2. Pancreatic resection Surgical resection will be performed 2-4 weeks after the end of radiation therapy. The surgical method and resection range depend on the surgeon's judgment at the time of surgery.~3. Adjuvant Chemotherapy Adjuvant chemotherapy will be given under the judgment of the oncologist from 4 weeks after surgical resection, considering the pathological findings (R0 or R1 resection status, etc.) and the patient's medical condition. Adjuvant chemotherapy includes gemcitabine alone, gemcitabine plus capecitabine combination therapy, and mFOLFIRINOX.
Study: NCT06378060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified transplantation system
Description: Conditioning regimen: fludarabine 30mg/m2×5\~6d,cyclophosphamide 50mg/kg×2d, melphalan 100mg/m2×1d aGVHD prophylaxis: PTCY 25mg/kg×2d, ATG 4.5mg/kg total, MMF 15mg/kg +5d\~+35d, Ruxolitinib 5mg bid -1d\~+50d and 2.5mg bid +51d\~+110d, CSA
Study: NCT05710796

Intervention type: BEHAVIORAL
Intervention: Difference in gender, response to disease, diagnostic test values
Description: Gender difference: Prevalence of disease in male vs female Response to disease: Which group is more prone to cardiac involvement Diagnostic tests: Diagnostic confirmation of disease

Intervention type: BEHAVIORAL
Intervention: Difference in gender, response to disease, diagnostic test values
Description: Gender difference: Prevalence of disease in male vs female Response to disease: Which group is more prone to cardiac involvement Diagnostic tests: Diagnostic confirmation of disease
Study: NCT06097286

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external oblique intercostal plane block
Description: o EOIP Group (ŋ=25): Patients will receive ultrasound guided External oblique intercostal plane block with 20 ml of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a total volume of 20 ml.) at the end of procedure, unilaterally or bilaterally according to the surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block
Description: o ESP Group (ŋ=25): Patients will receive ultrasound guided Erector spinae plane block with 20 ml of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a total volume of 20 ml.) at the end of procedure, unilaterally or bilaterally according to the surgery.
Study: NCT04238260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing Physical Therapy Usual Care
Description: The protocol is focused on the completion of a minimum of 30 minutes of weight-bearing, walking-related activities that progressively increase in intensity informed by heart rate and step counters over 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy Usual Care
Description: Usual physical therapy
Study: NCT05947383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin 25 mg oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Niacin 100 mg oral capsule
Study: NCT06385600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: Group L will recieve labetalol intravenous infusion (Trandate, Gsk) in a concentration of 10 mg/ ml, thus 50 mg/ml equals to 5 ml/hr. The starting infusion rate of the antihypertensive medication is 5 ml/hr for an 80 Kg patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentolamine
Description: Group P will receive phentolamine intravenous infusion (Rogitamine) in a concentration of 10 mg/ml, thus 1 µg/Kg/min equals to 4.8 ml/hr for an 80 Kg patient.
Study: NCT04788212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Behavioral Activation Therapy for Autism Spectrum Disorder
Description: This will be a modification of the Group Behavioral Activation Therapy program (Chu et al., 2009) for treatment of depression, anxiety and/or anger in autistic adults.
Study: NCT05710796

Intervention type: BEHAVIORAL
Intervention: Difference in gender, response to disease, diagnostic test values
Description: Gender difference: Prevalence of disease in male vs female Response to disease: Which group is more prone to cardiac involvement Diagnostic tests: Diagnostic confirmation of disease
Study: NCT04721158

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous glucose monitor
Description: Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
Study: NCT06183736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL237 tablets
Description: CVL237 tablets, 200 mg, taken with food once daily for 28 consecutive days as a treatment cycle.
Study: NCT05653401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate and diclofenac
Description: Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 1 g of Magnesium Sulfate solution diluted in 10 ml of saline solution administered over 2 to 4 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocain and diclofenac
Description: Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 10 ml of Lidocaine 1% solution administered over 2 to 4 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo and diclofenac
Description: Intramuscular injection of 75 mg of Diclofenac solution and 10 ml Intravenous injection of serum saline ( as a Placebo Comparator ) administered over 2 to 4 minutes.
Study: NCT06390046

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: Comparing videao laryngospy with traditional laryngoscopy